Related references
Note: Only part of the references are listed.Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas
G. K. Friedman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
Bin Fan et al.
INVESTIGATIONAL NEW DRUGS (2020)
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
Timothy F. Cloughesy et al.
NEURO-ONCOLOGY (2020)
Epigenetic Therapies for Cancer
Susan E. Bates
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Challenges to curing primary brain tumours
Kenneth Aldape et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Johann Foloppe et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02
Evanthia Galanis et al.
NEURO-ONCOLOGY (2018)
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
Frederick F. Lang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?
Alyssa M. Vanderbeek et al.
NEURO-ONCOLOGY (2018)
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Annick Desjardins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Adel Samson et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years
Xu Liu et al.
JAMA ONCOLOGY (2018)
Primary brain tumours in adults
Sarah Lapointe et al.
LANCET (2018)
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
Brian M. Alexander et al.
CLINICAL CANCER RESEARCH (2018)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang et al.
ANNALS OF ONCOLOGY (2018)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Martin J. van den Bent et al.
LANCET (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
James R. Perry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Landscape of Clinical Trials Evaluating the Theranostic Role of PET Imaging in Oncology: Insights from an Analysis of ClinicalTrials.gov Database
Yu-Pei Chen et al.
THERANOSTICS (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Phase II Weekly Vinblastine for Chemotherapy-Naive Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study
Alvaro Lassaletta et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G. Baumert et al.
LANCET ONCOLOGY (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme
Wilson Roa et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
Eudocia Q. Lee et al.
NEURO-ONCOLOGY (2015)
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Shota Tanaka et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)